SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-20-249206
Filing Date
2020-09-18
Accepted
2020-09-18 17:05:28
Documents
1
Group Members
VERSANT AFFILIATES FUND V, L.P.VERSANT OPHTHALMIC AFFILIATES FUND I, L.P.VERSANT SIDE FUND IV, L.P.VERSANT VENTURE CAPITAL V (CANADA) LPVERSANT VENTURE CAPITAL V, L.P.VERSANT VENTURE MANAGEMENT, LLCVERSANT VENTURES IV, LLCVERSANT VENTURES V (CANADA), L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d16950dsc13da.htm SC 13D/A 213015
  Complete submission text file 0001193125-20-249206.txt   214998
Mailing Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 650-233-2211
Versant Venture Capital IV, L.P. (Filed by) CIK: 0001456590 (see all company filings)

IRS No.: 263080195 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89674 | Film No.: 201184605
SIC: 2836 Biological Products, (No Diagnostic Substances)